Vaccine

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

6 months ago user

Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...

Humanity Supersedes Technology with Covid Vaccines

9 months ago user

Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

9 months ago user

Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...

Vaccine

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

Humanity Supersedes Technology with Covid Vaccines

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

You may have missed

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021